ArticleJournal of medical primatology2026
A Confirmatory, Dual Center Nonhuman Primate Study on the Efficacy of Novel Oropharyngeal Spray Immunization With an Adenoviral Vector Vaccine Against RSV-Important Lessons Learned.
Article in Journal of medical primatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundIn a randomized, blinded, dual center study across two European primate research facilities, we evaluated the immunogenicity and protective efficacy of a DNA prime-oropharyngeal adenoviral boost vaccination strategy against respiratory syncytial virus (RSV).
methodsRhesus macaques received an RSV fusion protein (F) DNA vaccine via electroporation, followed by two mucosal administrations of a recombinant adenovirus vector encoding the same antigen. Mock-vaccinated animals and a comparator group mimicking natural immunity induced by primary RSV infection were included as controls. Systemic and mucosal immune responses were monitored longitudinally.
resultsWe detected robust cellular and humoral immune responses, but with some variability between the two centers. Nevertheless, RSV-vaccinated animals demonstrated markedly reduced viral replication in the upper and lower respiratory tract after RSV challenge infection. Unexpected RSV-specific immunity in the control group at one single study site prevented confirmation of the predefined primary endpoint.
conclusionOur results support the potential of mucosal adenoviral boosting following DNA priming to induce protective immunity against RSV, while highlighting challenges associated with multi-center preclinical vaccine studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.